Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities Review
| Authors: | Falchi, L.; Vardhana, S. A.; Salles, G. A. |
| Review Title: | Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities |
| Abstract: | Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have shifted dramatically in the last 2 decades following the introduction of highly active immunotherapies such as rituximab. Since then, the field has continued to witness tremendous progress with the introduction of newer, more potent immunotherapeutics, including chimeric antigen receptor T-cell therapy, which have received regulatory approval for and currently play a significant role in the treatment of these diseases. Bispecific antibodies (BsAb) are a novel class of off-the-shelf T-cell redirecting drugs and are among the most promising immunotherapeutics for lymphoma today. BsAb may target various cell-surface antigens and exist in different formats. Anti-CD20xCD3 BsAb have demonstrated remarkable single-agent activity in patients with heavily pretreated B-NHL with a manageable toxicity profile dominated by T-cell overactivation syndromes. Much work remains to be done to define the optimal setting in which to deploy these drugs for B-NHL treatment, their ideal combination partners, strategies to minimize toxicity, and, perhaps most importantly, pharmacodynamic biomarkers of response and resistance. In this review, we provide an update on BsAb development in B-NHL, from discovery to clinical applications, highlighting the achievements, limitations, and future directions of the field. © 2023 The American Society of Hematology |
| Keywords: | treatment response; review; cancer combination chemotherapy; drug efficacy; drug safety; nonhuman; unspecified side effect; cancer patient; rituximab; t lymphocyte; t-lymphocytes; cancer immunotherapy; gene expression; tumor marker; cancer resistance; b cell lymphoma; lymphoma, b-cell; cd20 antigen; nonhodgkin lymphoma; effector cell; t lymphocyte activation; cd19 antigen; antibody dependent cellular cytotoxicity; cell mediated cytotoxicity; tumor-associated macrophage; clinical pharmacology; diffuse large b cell lymphoma; antibodies, bispecific; bispecific antibody; preclinical study; humans; human |
| Journal Title: | Blood |
| Volume: | 141 |
| Issue: | 5 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-02-02 |
| Start Page: | 467 |
| End Page: | 480 |
| Language: | English |
| DOI: | 10.1182/blood.2021011994 |
| PUBMED: | 36322929 |
| PROVIDER: | scopus |
| PMCID: | PMC9936308 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK authors: Gilles A. Salles -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work